{"doi":"10.1002/cncr.35750","title":"Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study","abstract":"BACKGROUND: Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity. METHODS: In this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single-agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility. RESULTS: The study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow-up of 101.2 months, median overall survival (OS) was 26.3 months (3-year rate, 44%; 5-year rate, 36%; 10-year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease-free survival between patients who did and who did not receive alemtuzumab. CONCLUSION: Alemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.","journal":"Cancer","year":2025,"id":538732,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9591,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":477410,"name":"Jun Yin","orcid":"0000-0003-3242-9664","position":1,"is_corresponding":false},{"id":278008,"name":"Gerard Lozanski","orcid":"0000-0002-5095-0456","position":2,"is_corresponding":false},{"id":1133944,"name":"Emily Curran","orcid":"0000-0001-8159-4733","position":3,"is_corresponding":false},{"id":1425603,"name":"Gregory Malnassy","orcid":"0000-0003-4794-7210","position":4,"is_corresponding":false},{"id":295280,"name":"Krzysztof Mrózek","orcid":"0000-0002-1408-5063","position":5,"is_corresponding":false},{"id":1425985,"name":"C. D. Bloomfield","orcid":null,"position":6,"is_corresponding":false},{"id":691944,"name":"Spero R. Cataland","orcid":"0000-0001-8977-6910","position":7,"is_corresponding":false},{"id":1425986,"name":"Noreen Fulton","orcid":null,"position":8,"is_corresponding":false},{"id":295290,"name":"Jonathan E. Kolitz","orcid":"0000-0003-2700-4784","position":9,"is_corresponding":false},{"id":570655,"name":"Betsy LaPlant","orcid":null,"position":10,"is_corresponding":false},{"id":1160534,"name":"Oudom Kour","orcid":null,"position":11,"is_corresponding":false},{"id":261015,"name":"Bayard L. Powell","orcid":null,"position":12,"is_corresponding":false},{"id":25439,"name":"Ravi Vij","orcid":"0000-0001-8795-3610","position":13,"is_corresponding":false},{"id":284267,"name":"Eunice S. Wang","orcid":"0000-0002-8644-0968","position":14,"is_corresponding":false},{"id":1189763,"name":"David L. Grinblatt","orcid":"0000-0002-2118-0042","position":15,"is_corresponding":false},{"id":34476,"name":"Richard M. Stone","orcid":"0000-0002-7526-2633","position":16,"is_corresponding":false},{"id":233348,"name":"Geoffrey L. Uy","orcid":"0000-0002-7809-0996","position":17,"is_corresponding":false},{"id":305983,"name":"Richard A. Larson","orcid":"0000-0001-9168-3203","position":18,"is_corresponding":false},{"id":230930,"name":"Wendy Stock","orcid":"0000-0002-8349-9200","position":19,"is_corresponding":false},{"id":565017,"name":"Marlise R. Luskin","orcid":"0000-0002-5781-4529","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-19T02:52:25.799399Z","pmid":"39916320","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}